Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

More symptoms during initial COVID infection increase the risk of long-term effects.

This phase 1 study reported that after administering supratherapeutic doses of cortexolone 17α‐propionate, a topical antiandrogen intended for hair loss treatment, there was no effect on the QTc interval, indicating no measurable cardiac safety concerns in the concentration range tested.

In this study, patients with alopecia areata who didn't initially respond to ritlecitinib at Week 24 showed improved response rates by Week 48, with up to 34% achieving better hair regrowth outcomes.

In a phase 2 trial, researchers tested a topical formulation for alopecia areata and found significant hair regrowth with the treatment, but these improvements did not lead to substantial enhancements in health-related quality of life.

This study reported that topical BPM31543 was safe and well-tolerated for patients on taxane-based chemotherapy, with some efficacy indicated in reducing hair loss at all dosages tested.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

This study found that treatment with ritlecitinib or brepocitinib was effective in improving scalp hair loss for patients with alopecia areata over 24 weeks compared to placebo.

This phase II study found that gemcitabine plus paclitaxel showed promising activity and manageable toxicity as first-line therapy for recurrent or metastatic breast cancer, with a 35% overall response rate.

This study found that MK-5108 is well tolerated at high doses as monotherapy in cancer patients, showing stable disease and some antitumor activity, particularly in combination with docetaxel.

This study explored whether using topical minoxidil can temporarily increase hair shedding, but results are not reported.

Docetaxel and oxaliplatin are effective and have manageable side effects for recurrent platinum-sensitive ovarian cancer.

In this randomized, placebo-controlled trial, adults with severe chronic alopecia areata who received deuruxolitinib showed significant hair regrowth compared to placebo over 24 weeks, and the treatment was generally well-tolerated, though long-term effects remain unexamined.

In this study, a 300 mcg daily testosterone patch significantly increased satisfying sexual episodes and sexual desire in postmenopausal women with hypoactive sexual desire disorder not receiving estrogen, compared to placebo.

This study found that treatment with ritlecitinib led to significant scalp hair regrowth in patients with alopecia areata at Weeks 24 and 48, with higher response rates observed in those receiving 50 mg compared to 30 mg doses.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

Baricitinib is generally safe for long-term use in treating severe alopecia areata.

In this study, neoadjuvant treatment with durvalumab combined with albumin-bound paclitaxel and carboplatin in patients with driver gene-negative stage III NSCLC showed a 65% objective response rate and was associated with high pathological response rates and improved immune function, with most adverse events being mild.

Among men with androgenetic alopecia, this study found that taking 5 mg of KX-826 twice daily significantly increased hair count compared to a placebo, with the treatment being well-tolerated and no serious adverse effects reported.

In this study, the expression of certain hair follicle-related genes differed between growth phases in Angora goats, with HOXC13 showing overexpression during the anagen phase, potentially influencing the mohair's shine and texture.

This study found that essential oils boost hair growth activity in dermal papilla cells by scavenging reactive oxygen species and upregulating growth factor biomarkers.

In this study, topical application of fibroblast growth factors was found to promote hair growth by inducing and prolonging the anagen phase in telogenic C57BL/6 mice, suggesting potential as hair growth-promoting agents.

In this study, oral administration of Crataegus pinnatifida extract was associated with hair growth promotion in mice by inducing anagen phase and enhancing cell signaling related to hair follicle development.

In this study, the researchers observed that MMP-2 and MMP-9 significantly fluctuated with the hair growth cycle in mice, suggesting their important role in hair development.

In this study, Lespedeza bicolor extract was found to enhance dermal papilla cell proliferation and extend the anagen phase in mice, suggesting its potential as a treatment for alopecia.

In this study, researchers found that recombinant human HAPLN1 promoted hair growth in mice and human hair matrix cells by activating specific signaling pathways, suggesting it may offer a potential hair loss treatment with fewer side effects than existing medications.

In this study, researchers found that a cold atmospheric plasma-activated hydrogel containing interleukin-2 significantly enhanced hair regeneration in a depilated mouse model, promoting larger hair follicles and faster hair growth phase transition, suggesting it as a potential treatment for hair loss.

In this study, researchers developed a promising transdermal agent using Triton X-100-modified polyethyleneimine that successfully delivered genetic material to hair follicle cells in mice, potentially alleviating hair loss due to androgenetic alopecia by promoting cell proliferation and inhibiting apoptosis.

Recombinant Filaggrin-2 microneedles effectively promote hair growth and repair in hair loss.

This study found that HOXC13 gene expression was significantly higher during the anagen phase in Angora goats, potentially contributing to the mohair's shiny and silky nature.

This study found that blue light at a wavelength of 453 nm promoted hair growth ex vivo, potentially through interacting with OPN3 receptors in human hair follicles.